4.7 Editorial Material

Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?

Related references

Note: Only part of the references are listed.
Article Oncology

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

Justyna M. Przystal et al.

Summary: The imipridone ONC201 and its derivative ONC206 significantly reduce cell viability in pediatric diffuse midline gliomas (DMGs) and prolong the survival of DMG PDX models. Both drugs impair tumor cell growth and survival by activating mitochondrial metabolism and the integrative stress response (ISR), and trigger cell lineage differentiation. These findings are of great importance for the treatment of pediatric DMGs.

NEURO-ONCOLOGY (2022)

Editorial Material Oncology

ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma

Benjamin Purow

NEURO-ONCOLOGY (2022)

Review Clinical Neurology

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials

Nicholas A. Vitanza et al.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2019)

Article Cell Biology

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

Grant L. Lin et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Article Oncology

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

Mark N. Stein et al.

CLINICAL CANCER RESEARCH (2017)